The two monoclonal antibodies are displayed after a press conference at Tsinghua University in Beijing on December 9, 2021, after China's drug authority granted emergency approval on December 8 for the country's first specialised treatment against Covid-19, found in clinical trials to significantly reduce hospitalisations and deaths among high-risk patients. (Photo by Noel Celis / AFP)